Filament Begins First Ever FDA-Approved Clinical Trial On Naturally-Derived Psychedelic Drugs

Clinical-stage natural psychedelics company Filament Health Corp. (OTCQB: FLHLF )  announced it will start providing patients with doses of the first FDA-approved study directly administering psilocin and psilocybin derived from mushrooms, as opposed to manufactured synthetic substances. The phase 1 clinical trial , to be conducted at the University of California San Francisco's Translational Psychedelic Research Program (TrPR) and supervised by Dr. Joshua Woolley  will investigate three of Filament's proprietary botanical drug candidates, naturally extracted and stabilized forms of the psychedelic compounds found in certain mushrooms.  The study’s goal is to compare the physiological and ... Full story available on